Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01635127
Other study ID # USZ-DER-AAN-017
Secondary ID
Status Recruiting
Phase Phase 2
First received July 3, 2012
Last updated September 26, 2016
Start date June 2012
Est. completion date May 2017

Study information

Verified date September 2016
Source University of Zurich
Contact Antonios Kolios, MD
Phone +41 (0)44 255 11 11
Email antonios.kolios@usz.ch
Is FDA regulated No
Health authority Switzerland: Swissmedic
Study type Interventional

Clinical Trial Summary

Evaluation whether canakinumab leads to improvement of urticaria


Description:

Single center prospective placebo-controlled cross-over phase II study.

- To assess if canakinumab can induce clinical improvement and/or complete clinical remission of chronic idiopathic urticaria at week 4 as compared to placebo

- To compare canakinumab and placebo treated patients in the percentage who achieve complete clinical remission at week 1, 2, 4, and 8.

- To compare the percentage with clinical improvement as measured by UAS7 score at week 1, 2, 4, and 8 in canakinumab and placebo treated patients

- To compare the percentage of canakinumab and placebo treated patients with 75% and 100% improvement of their baseline (Run-in-period) UAS7 score at week 1,2,4,and 8

- To compare the daily wheal score for Days 1 to 7 in canakinumab and placebo treated patients


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date May 2017
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion criteria

- Diagnosis of chronic idiopathic urticaria for more than 6 weeks as confirmed by clinical and, if necessary, histological examination

- CIU of moderate to severe severity defined by all of the following

- Physician severity score of 2 or 3 (on a scale from 0 - 3)

- Run-in period of the diary-based UAS7 score of > 21 (on a scale from 0 - 42)

- Symptomatic despite use of non-sedating antihistamine with or without concomitant leukotriene antagonist/corticosteroids

- Use of maintenance non-sedating antihistamine at a stable dose for at least 1 week prior to entering run-in period

- Maintenance corticosteroids at a dose of <20 mg/day or <0.4 mg/kg stable for at least the week prior to study entry for treatment of the patient's CIU will be allowed.

- Age: > 18 years.

- Signed informed consent

- Negative or unreactive QuantiFERON test (QFT-TB G In-Tube) or history of adequate treatment of active or latent tuberculosis.

Exclusion criteria:

- Age < 18 or > 70 years

- History of cancer except for treated basal cell carcinoma of the skin

- With active or recurrent bacterial, fungal or viral infection at the time of enrollment, including patients with evidence of Human Immunodeficiency Virus (HIV) infection, Hepatitis B and Hepatitis C infection, active or untreated latent tuberculosis.

- Patients currently treated with systemic immunosuppressive agents or following treatments in the specified period before the baseline visit:

- corticosteroids =20 mg/day or >0.4 mg/kg for 1 week prior to study entry;

- leukotriene antagonists for 1 week prior to study entry

- colchicine, dapsone or mycophenolate mofetil for 3 weeks;

- etanercept, leflunomide (documentation of a completion of a full cholestyramine elimination treatment after most recent leflunomide use will be required), thalidomide or ciclosporin for 4 weeks;

- adalimumab or intravenous immunoglobulin for 8 weeks;

- infliximab, 6-mercaptopurine, azathioprine, cyclophosphamide or chlorambucil for 12 weeks

- Live vaccinations within 3 months prior to the start of the trial, during the trial, and up to 3 months following the last dose

- Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product,

- Pregnant or lactating women, patients (men or women) planning a pregnancy during the duration of the study, lack of safe contraception.

- Safe contraception is defined as follows:

- Double-barrier contraception such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices together with condom use.

- Both men and women must use safe contraception (double-barrier as defined above) during the duration of the study and until 6 months after the study.

- Please note that female subjects who are surgically sterilized/hysterectomized or post-menopausal for longer than 2 years are not considered as being of child bearing potential.

- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the subject.

- Participation in another study with investigational drug within the 30 days preceding and during the present study.

- Previous enrolment into the current study.

- Enrolment of the investigator, his/her family members, employees and other dependent persons.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Canakinumab
150mg s.c.
Placebo
Constituent of canakinumab

Locations

Country Name City State
Switzerland University Hospital Zurich, Division of Dermatology Zurich

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complete clinical remission Improvement of urticaria within 4 weeks, objective measurements daily wheal score and UAS7 4 weeks No
See also
  Status Clinical Trial Phase
Completed NCT02814630 - Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria N/A
Completed NCT01803763 - Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients Phase 2/Phase 3
Completed NCT00536380 - Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849) Phase 4
Completed NCT03183024 - Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody Phase 4
Completed NCT00757562 - Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994) Phase 3
Completed NCT03858634 - A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases Phase 2
Completed NCT01292473 - A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1) Phase 3
Completed NCT00866788 - A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1) Phase 2
Recruiting NCT05936567 - Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Phase 2
Not yet recruiting NCT02166151 - Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria Phase 3
Recruiting NCT02031679 - Efficacy and Safety of CRTH2 Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines Phase 2
Recruiting NCT00346606 - The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria Phase 4
Completed NCT01287117 - A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment Phase 3
Completed NCT01264939 - A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists Phase 3
Completed NCT03406325 - Mast Cell Activation Test in Allergic Disease
Not yet recruiting NCT04175704 - Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria Phase 1
Withdrawn NCT01030120 - Etanercept for the Treatment of Chronic Urticaria Phase 2/Phase 3
Completed NCT00264303 - CUTE (Chronic Urticaria Treatment Evaluation) Phase 4
Recruiting NCT05774639 - Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria Phase 3
Completed NCT01599637 - Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment Phase 2